BioCentury | Jan 11, 2017
Clinical News

Orthovisc-T regulatory update

...Anika received CE Mark approval for Orthovisc-T sodium hyaluronate to treat pain and restore function in...
...acid. Anika Therapeutics Inc. (NASDAQ:ANIK), Bedford, Mass. Product: Orthovisc-T sodium hyaluronate Business: Musculoskeletal Alicia Parker Anika Therapeutics Inc. Orthovisc-T...
BioCentury | Nov 3, 2014
Finance

Shooting F-stars

...grew 24% to $22.1M from $17.8M in 3Q13 primarily due to sales of osteoarthritis products Orthovisc...
BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

...Vogelxo testosterone Upsher-Smith Laboratories Inc. Hypogonadism ü Byetta exenatide AstraZeneca plc (LSE:AZN; NYSE:AZN) Diabetes ü Orthovisc...
BioCentury | Nov 4, 2013
Finance

Calithera metabolizes

...primarily due to increased domestic and international sales of viscosupplementation products, which include osteoarthritis treatment Orthovisc...
BioCentury | Aug 5, 2013
Finance

Deciphering Dicerna's future

...to $20.8M from $19.6M in 2Q12 primarily due to increased domestics sales of osteoarthritis treatment Orthovisc...
BioCentury | May 6, 2013
Finance

Perpetual acceleration

...to $15.2M from $14.4M in 1Q12 primarily due to increased domestics sales of osteoarthritis treatment Orthovisc...
BioCentury | Mar 4, 2013
Finance

Amgen's Omontys bounce

...23% to $22.6M from $18.4M in 4Q11 primarily due to sales of its osteoarthritis treatment Orthovisc...
BioCentury | Nov 5, 2012
Finance

Investors not going A-LONG

...scale-up issue at its Bedford, Mass., manufacturing facility that prevented it from filling orders for Orthovisc...
BioCentury | Aug 6, 2012
Finance

Burrill taps offshore

...2Q12 revenues grew 22% to $19.6M from $16.1M in 2Q11, primarily due to sales of Orthovisc...
BioCentury | May 7, 2012
Finance

BG-12 deal keeps on giving

...$40.7 $181.5 1Q12 revenues grew 22% to $14.4M from $11.7M, primarily due to sales of Orthovisc...
Items per page:
1 - 10 of 66